BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34990870)

  • 1. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
    See SHC; Siziopikou KP
    Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
    Bossuyt V; Spring L
    Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
    Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
    J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
    Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
    Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
    Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
    Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
    Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.
    Keune JD; Jeffe DB; Schootman M; Hoffman A; Gillanders WE; Aft RL
    Am J Surg; 2010 Apr; 199(4):477-84. PubMed ID: 20359567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in the treatment of breast cancer.
    Redden MH; Fuhrman GM
    Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy in breast cancers.
    Masood S
    Womens Health (Lond); 2016 Sep; 12(5):480-491. PubMed ID: 27885165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
    Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
    Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
    Rabban JT; Glidden D; Kwan ML; Chen YY
    Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.